• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

葡萄牙使用阿扎胞苷治疗的急性髓系白血病患者的临床结局：一项回顾性多中心研究。

Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study.

作者信息

Almeida António, Ferreira Ana Rita, Costa Maria João, Silva Sofia, Alnajjar Khalil, Bogalho Isabel, Pierdomenico Francesca, Esteves Susana, Alpoim Mafalda, Braz Gil, Cortesão Emilia, Pinto Ricardo

机构信息

Serviço de Hematologia, Instituto Português de Oncologia de Lisboa, Francisco Gentil, Lisbon, Portugal.

Serviço de Hematologia, Centro Hospitalar Lisboa Norte, Hospital Santa Maria, Lisboa, Portugal.

出版信息

Leuk Res Rep. 2016 Dec 23;7:6-10. doi: 10.1016/j.lrr.2016.12.002. eCollection 2017.

DOI:10.1016/j.lrr.2016.12.002
PMID:28066705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5200877/
Abstract

Retrospective data was collected from 77 elderly acute myeloid leukemia (AML) patients treated with Azacitidine (AZA) and 50 elderly AML patients treated with intensive chemotherapy (IC) from 4 Portuguese Hospitals. Median OS was 10.6 months in those receiving AZA as 1st line. Response (overall response rate 44%) had a significant impact on overall survival (p=<0.0001). Median OS of the comparator IC cohort was significantly inferior to that observed in the cohort treated with AZA in first line (p=0.0104). These results support the efficacy of AZA in AML in the elderly in any line of treatment.

摘要

从4家葡萄牙医院收集了77例接受阿扎胞苷（AZA）治疗的老年急性髓系白血病（AML）患者以及50例接受强化化疗（IC）的老年AML患者的回顾性数据。接受AZA作为一线治疗的患者中位总生存期为10.6个月。缓解情况（总缓解率44%）对总生存期有显著影响（p<0.0001）。对照IC队列的中位总生存期显著低于一线接受AZA治疗的队列（p=0.0104）。这些结果支持了AZA在老年AML患者任何治疗线中的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/49bb6b1c1713/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/987e7a82cd52/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/4cd1a61901a6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/7390c9e2a8c4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/49bb6b1c1713/gr4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/987e7a82cd52/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/4cd1a61901a6/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/7390c9e2a8c4/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db46/5200877/49bb6b1c1713/gr4.jpg

相似文献

1
Clinical outcomes of AML patients treated with Azacitidine in Portugal: A retrospective multicenter study.葡萄牙使用阿扎胞苷治疗的急性髓系白血病患者的临床结局：一项回顾性多中心研究。
Leuk Res Rep. 2016 Dec 23;7:6-10. doi: 10.1016/j.lrr.2016.12.002. eCollection 2017.
2
Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+).在一大组根据MRC/LRF评分分层的老年急性髓系白血病患者中使用一线阿扎胞苷的真实生活经验：来自扩展的国际E-ALMA系列研究（E-ALMA+）的结果
Leuk Lymphoma. 2018 May;59(5):1113-1120. doi: 10.1080/10428194.2017.1365854. Epub 2017 Aug 24.
3
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry.阿扎胞苷与地西他滨治疗不适合新诊断急性髓系白血病患者的疗效比较：PETHEMA注册研究结果
Cancers (Basel). 2022 May 9;14(9):2342. doi: 10.3390/cancers14092342.
4
Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.阿扎胞苷用于急性髓系白血病患者的一线治疗：通过国际3期试验数据与AGMT研究组奥地利阿扎胞苷登记处登记数据的直接比较确立的可重复性疗效
Int J Mol Sci. 2017 Feb 15;18(2):415. doi: 10.3390/ijms18020415.
5
Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.阿扎胞苷与强化化疗作为老年急性髓系白血病一线治疗的对比分析。
Ann Hematol. 2018 Oct;97(10):1767-1774. doi: 10.1007/s00277-018-3374-x. Epub 2018 Jun 10.
6
Efficacy and toxicity of Decitabine in patients with acute myeloid leukemia (AML): A multicenter real-world experience.地西他滨治疗急性髓系白血病（AML）患者的疗效与毒性：一项多中心真实世界研究经验
Leuk Res. 2019 Jan;76:33-38. doi: 10.1016/j.leukres.2018.11.015. Epub 2018 Nov 28.
7
The Role of Azacitidine in the Treatment of Elderly Patients with Acute Myeloid Leukemia: Results of a Retrospective Multicenter Study.阿扎胞苷在老年急性髓系白血病治疗中的作用：一项回顾性多中心研究结果
Turk J Haematol. 2016 Dec 1;33(4):273-280. doi: 10.4274/tjh.2015.0203. Epub 2016 Apr 18.
8
Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.根据治疗方法分析老年继发性急性髓系白血病患者的特征及预后。
Cancer. 2017 Aug 15;123(16):3050-3060. doi: 10.1002/cncr.30704. Epub 2017 Apr 7.
9
Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.老年急性髓系白血病患者的治疗决策：传统强化化疗与去甲基化药物治疗对比
Ann Hematol. 2017 Nov;96(11):1801-1809. doi: 10.1007/s00277-017-3104-9. Epub 2017 Aug 21.
10
Azacitidine for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia.阿扎胞苷治疗骨髓增生异常综合征、慢性粒单核细胞白血病和急性髓系白血病。
Health Technol Assess. 2010 May;14 Suppl 1:69-74. doi: 10.3310/hta14Suppl1/10.

引用本文的文献

1
JCMM Annual Review on Advances in Biotechnology for the Treatment of Haematological Malignancies: A Review of the Latest In-Patient Developments 2024-2025.《JCMM关于血液恶性肿瘤治疗生物技术进展的年度回顾：2024 - 2025年最新住院治疗进展回顾》
J Cell Mol Med. 2025 Jul;29(13):e70700. doi: 10.1111/jcmm.70700.
2
Real-World Outcome and Prognostic Factors in MDS Patients Treated with Azacitidine-A Retrospective Analysis.接受阿扎胞苷治疗的骨髓增生异常综合征患者的真实世界结局及预后因素——一项回顾性分析
Cancers (Basel). 2024 Mar 29;16(7):1333. doi: 10.3390/cancers16071333.
3
Comparison of Hypomethylator Monotherapy with Hypomethylator plus Chemotherapy for Intermediate/High-Risk MDS or AML: A Meta-Analysis.

本文引用的文献

1
The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study.合并疾病史对髓系白血病和骨髓瘤全因死亡率及癌症特异性死亡率的影响——一项基于瑞典人群的研究
BMC Cancer. 2015 Nov 5;15:850. doi: 10.1186/s12885-015-1857-x.
2
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts.阿扎胞苷对比传统治疗方案用于新诊断的原始细胞比例>30%的老年急性髓系白血病患者的国际3期研究。
Blood. 2015 Jul 16;126(3):291-9. doi: 10.1182/blood-2015-01-621664. Epub 2015 May 18.
3
Big data analysis of treatment patterns and outcomes among elderly acute myeloid leukemia patients in the United States.
低甲基化剂单药治疗与低甲基化剂联合化疗治疗中/高危骨髓增生异常综合征或急性髓系白血病的比较：一项荟萃分析。
J Cancer. 2020 Mar 4;11(10):2972-2980. doi: 10.7150/jca.40614. eCollection 2020.
4
Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study.根据治疗类型和治疗线数分析217例急性红白血病患者的临床结局：一项回顾性多国研究
Int J Mol Sci. 2017 Apr 14;18(4):837. doi: 10.3390/ijms18040837.
美国老年急性髓系白血病患者治疗模式与结局的大数据分析
Ann Hematol. 2015 Jul;94(7):1127-38. doi: 10.1007/s00277-015-2351-x. Epub 2015 Mar 20.
4
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction.不适合强化疗的急性髓系白血病患者一线阿扎胞苷治疗：临床应用与预后预测。
Leuk Res. 2015 Mar;39(3):296-306. doi: 10.1016/j.leukres.2014.12.013. Epub 2014 Dec 31.
5
Azacitidine for the treatment of relapsed and refractory AML in older patients.阿扎胞苷治疗老年复发/难治性 AML。
Leuk Res. 2015 Feb;39(2):124-30. doi: 10.1016/j.leukres.2014.11.009. Epub 2014 Nov 24.
6
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group.302例世界卫生组织定义的急性髓系白血病患者使用阿扎胞苷的情况：AGMT研究组奥地利阿扎胞苷登记处的结果
Ann Hematol. 2014 Nov;93(11):1825-38. doi: 10.1007/s00277-014-2126-9. Epub 2014 Jun 21.
7
Efficacy and tolerability of 5-day azacytidine dose-intensified regimen in higher-risk MDS.高危 MDS 中 5 天阿扎胞苷剂量强化方案的疗效和耐受性。
Ann Hematol. 2013 Sep;92(9):1201-6. doi: 10.1007/s00277-013-1762-9. Epub 2013 Apr 21.
8
Azacitidine in the treatment of therapy related myelodysplastic syndrome and acute myeloid leukemia (tMDS/AML): a report on 54 patients by the Groupe Francophone Des Myelodysplasies (GFM).阿扎胞苷治疗治疗相关性骨髓增生异常综合征和急性髓系白血病（tMDS/AML）：法国骨髓增生异常综合征研究组（GFM）54 例报告。
Leuk Res. 2013 Jun;37(6):637-40. doi: 10.1016/j.leukres.2013.02.014. Epub 2013 Mar 15.
9
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.急性髓系白血病中综合基因分析的预后相关性。
N Engl J Med. 2012 Mar 22;366(12):1079-89. doi: 10.1056/NEJMoa1112304. Epub 2012 Mar 14.
10
Azacitidine prolongs overall survival and reduces infections and hospitalizations in patients with WHO-defined acute myeloid leukaemia compared with conventional care regimens: an update.与传统治疗方案相比，阿扎胞苷可延长世界卫生组织定义的急性髓系白血病患者的总生存期，并减少感染和住院次数：一项更新。
Ecancermedicalscience. 2008;2:121. doi: 10.3332/ecancer.2008.121. Epub 2008 Dec 10.